LabCorp neutralizing antibody test could help screen recovered COVID-19 patients

By staff writers

June 25, 2020 -- LabCorp has launched a new neutralizing antibody test that it says will be useful in the development of vaccines and in screening the plasma of recovered COVID-19 patients.

The test -- PhenoSense -- will be provided to biopharmaceutical companies, hospitals, and plasma screening facilities, the company said in a statement. One area of development that has been promising is the use of antibodies from convalescent COVID-19 patients as a means of prevention or treatment. The test may be helpful for defining neutralizing antibody activity and therapeutic efficacy of plasma for transfer to sick patients, according to the company.

Mount Sinai files COVID-19 quantitative serology test
Mount Sinai Health System has submitted a request for an emergency use authorization to the U.S. Food and Drug Administration covering a quantitative...
LabCorp gives employers a hand with screening staff for coronavirus
LabCorp is launching return-to-work services to help employers screen their staff for COVID-19, including antibody blood tests.
LabCorp expands access to at-home coronavirus testing
LabCorp is now opening up its at-home coronavirus molecular diagnostic testing to consumers, having initially offered it to healthcare workers and first...
LabCorp opens coronavirus antibody test booking to consumers
LabCorp is now offering immunoglobulin G antibody testing directly to individuals through its website
LabCorp wins FDA clearance for at-home COVID-19 test
LabCorp has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its Pixel by LabCorp COVID-19 at-home test kit....

Copyright © 2020

Last Updated ls 6/25/2020 10:07:13 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current